首页> 外文期刊>Pharmacological research: The official journal of The Italian Pharmacological Society >Influence of baseline values on lipids, lipoproteins and fibrinolytic parameters during amlodipine treatment of hypertension in Japanese patients.
【24h】

Influence of baseline values on lipids, lipoproteins and fibrinolytic parameters during amlodipine treatment of hypertension in Japanese patients.

机译:在氨氯地平治疗高血压的日本患者中,基线值对脂质,脂蛋白和纤溶参数的影响。

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

Twenty-four Japanese hypertensive patients of both sexes, grouped as having 'medium' and 'high' baseline total lipid values, had their serum lipids, lipoproteins and plasma fibrinolytic parameters, renin and noradrenaline levels determined after 3 months of amlodipine treatment. For the patients with 'medium baseline values', total plasminogen activator inhibitor-1 (PAI-1) and t-PA-PAI-1 complex levels decreased, while the changes in lipids and lipoproteins were not significant after amlodipine treatment. For the patients with 'high baseline values', the mean triglyceride and very low density lipoprotein cholesterol (VLDLC) levels were reduced while the reductions in total and free PAI-1 and the increase in tissue plasminogen (t-PA) levels were not significant after amlodipine treatment. Negative correlations were observed between t-PA and high density lipoprotein cholesterol (HDLC) and HDLC/total cholesterol (TC) ratio in the patients with 'medium baseline values' while t-PA positively correlated with HDLC/TC ratio in patients with 'high baseline values'. The mean levels of renin and noradrenaline remained unchanged before and after amlodipine treatment in the two baseline groups. These findings show that baseline lipid levels of the hypertensive patients could influence lipids and fibrinolytic parameters differently during amlodipine treatment. The baseline lipid levels also influenced the metabolic association between lipids and fibrinolytic function in hypertensive patients during amlodipine treatment. The baseline total lipid values could therefore provide explanations for the complex metabolic interaction between lipids and fibrinolytic function as well as for the antiatherogenic actions of amlodipine treatment in hypertensive patients. Copyright 2000 Academic Press.
机译:氨氯地平治疗3个月后确定的24位日本高血压男女患者被分为“中”和“高”基线总脂质值,其血清脂质,脂蛋白和血浆纤溶参数,肾素和去甲肾上腺素水平确定。对于具有“中等基线值”的患者,氨氯地平治疗后总纤溶酶原激活物抑制剂1(PAI-1)和t-PA-PAI-1复合物水平降低,而脂质和脂蛋白的变化不明显。对于具有“高基线值”的患者,平均甘油三酸酯和极低密度脂蛋白胆固醇(VLDLC)水平降低,而总PAI-1和游离PAI-1的降低以及组织纤溶酶原(t-PA)的升高并不显着氨氯地平治疗后。在“中基线值”患者中,t-PA与高密度脂蛋白胆固醇(HDLC)和HDLC /总胆固醇(TC)比之间呈负相关,而在“高基线”患者中,t-PA与HDLC / TC比成正相关基准值”。在两个基线组中,氨氯地平治疗前后肾素和去甲肾上腺素的平均水平保持不变。这些发现表明,在氨氯地平治疗期间,高血压患者的基线血脂水平可能会不同地影响血脂和纤溶参数。在氨氯地平治疗期间,基线血脂水平还影响高血压患者血脂与纤溶功能之间的代谢关联。因此,基线总脂质值可以为脂质与纤溶功能之间复杂的代谢相互作用以及高血压患者氨氯地平治疗的抗动脉粥样硬化作用提供解释。版权所有2000学术出版社。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号